— Know what they know.
Not Investment Advice

PROT OTC

Proteonomix, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -0.0% 5Y: -95.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 40 · $791 mcap · 7M float · 0.919% daily turnover
Smart Money Score
Watch 0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.0M
52W Range0.000001-0.0001
Volume66,200
Avg Volume60,316
Beta3.14
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Moshe Cohen
Employees164
SectorHealthcare
IndustryBiotechnology
IPO Date1997-07-31
145 Highview Terrace
Hawthorne, NJ 07506
US
973-949-4193
About Proteonomix, Inc.

Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms